p53-based Cancer Therapy paper

2014-11-23

p53-based Cancer Therapy paper

placemark:
ADENOVIRUS BASED THERAPY ONYX 015

p53-based Cancer Therapy
Cold Spring Harbor Perspectives in Biology
2010
A-Star Singapore and Karolinska Institutet Stockholm Sweden paper


Gene therapy using
wild-type p53, delivered by adenovirus vectors, is now in widespread use in China

Sophisticated animal models have
shown that activation of the p53 response in
even advanced tumors can be curative

p53 gene therapy, Gendicine, is approved
in China and its US counterpart, Advexin, has
shown activity in number of clinical trials.

p53 based vac-
cines in cancer patients


Finally drug combi-
nations have been developed that can selectively
kill cancer cells that lack p53 function while
protecting normal cells (Sur et al. 2009)

Jack Roth was the ?rst to attempt p53 gene
therapy in man. In 1996 he used direct injection
of a retroviral vector expressing human p53
under the control of an actin promoter to treat
non-small cell lung carcinoma (NSCLC)


although neutralizing antibodies can re-
duce infectivity, this is not as big a problem
as anticipated when measured in the clinic


Using this initial approach many thousands of
patients have received p53-based gene therapies
in clinical trials mostly in the USA and in China


Although some remarkable clinical cases have
been reported Advexin has not yet won approval
from the FDA and very recently the company
developing it was closed


The
analysis of 2500 patients treated by Gendicine
has been published and the production facilities
and ?lings of the company are to a very high
international standard